Chromatography Purification of Canine Adenoviral Vectors

被引:18
作者
Mercedes Segura, Maria [2 ]
Puig, Meritxell [1 ,2 ]
Monfar, Merce [2 ]
Chillon, Miguel [2 ,3 ]
机构
[1] Univ Autonoma Barcelona, Dept Engn Quim, E-08193 Barcelona, Spain
[2] Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy CBATEG, E-08193 Barcelona, Spain
[3] ICREA, Barcelona, Spain
关键词
CONDITIONALLY REPLICATING ADENOVIRUS; RECOMBINANT ADENOVIRUS; ADENOASSOCIATED VIRUS; EMPTY CAPSIDS; GENE-THERAPY; TYPE-2; IMMUNIZATION; TRANSPORT; IMMUNITY; VACCINE;
D O I
10.1089/hgtb.2012.058
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Canine adenovirus vectors (CAV2) are currently being evaluated for gene therapy, oncolytic virotherapy, and as vectors for recombinant vaccines. Despite the need for increasing volumes of purified CAV2 preparations for preclinical and clinical testing, their purification still relies on the use of conventional, scale-limited CsCl ultracentrifugation techniques. A complete downstream processing strategy for CAV2 vectors based on membrane filtration and chromatography is reported here. Microfiltration and ultra/diafiltration are selected for clarification and concentration of crude viral stocks containing both intracellular and extracellular CAV2 particles. A DNase digestion step is introduced between ultrafiltration and diafiltration operations. At these early stages, concentration of vector stocks with good recovery of viral particles (above 80%) and removal of a substantial amount of protein and nucleic acid contaminants is achieved. The ability of various chromatography techniques to isolate CAV2 particles was evaluated. Hydrophobic interaction chromatography using a Fractogel propyl tentacle resin was selected as a first chromatography step, because it allows removal of the bulk of contaminating proteins with high CAV2 yields (88%). An anion-exchange chromatography step using monolithic supports is further introduced to remove the remaining contaminants with good recovery of CAV2 particles (58-69%). The main CAV2 viral structural components are visualized in purified preparations by electrophoresis analyses. Purified vector stocks contained intact icosahedral viral particles, low contamination with empty viral capsids (10%), and an acceptable total-to-infectious particle ratio (below 30). The downstream processing strategy that was developed allows preparation of large volumes of high-quality CAV2 stocks.
引用
收藏
页码:182 / 197
页数:16
相关论文
共 52 条
[1]   Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies [J].
Alcayaga-Miranda, F. ;
Cascallo, M. ;
Rojas, J. J. ;
Pastor, J. ;
Alemany, R. .
CANCER GENE THERAPY, 2010, 17 (11) :792-802
[2]   Production and formulation of adenovirus vectors [J].
Altaras, NE ;
Aunins, JG ;
Evans, RK ;
Kamen, A ;
Konz, JO ;
Wolf, JJ .
GENE THERAPY AND GENE DELIVERY SYSTEMS, 2005, 99 :193-260
[3]   Canine adenoviruses elicit both humoral and cell-mediated immune responses against rabies following immunisation of sheep [J].
Bouet-Cararo, Coraline ;
Contreras, Vanessa ;
Fournier, Annie ;
Jallet, Corinne ;
Guibert, Jean Michel ;
Dubois, Eric ;
Thiery, Richard ;
Breard, Emmanuel ;
Tordo, Noel ;
Richardson, Jennifer ;
Schwartz-Cornil, Isabelle ;
Zientara, Stephan ;
Klonjkowski, Bernard .
VACCINE, 2011, 29 (06) :1304-1310
[4]   An Update on Canine Adenovirus Type 2 and Its Vectors [J].
Bru, Thierry ;
Salinas, Sara ;
Kremer, Eric J. .
VIRUSES-BASEL, 2010, 2 (09) :2134-2153
[5]   Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates [J].
Brunetti-Pierri, N ;
Palmer, DJ ;
Beaudet, AL ;
Carey, KD ;
Finegold, M ;
Ng, P .
HUMAN GENE THERAPY, 2004, 15 (01) :35-46
[6]   Chromatooraphic purification of recombinant adenoviral and adeno-associated viral vectors: methods and implications [J].
Burova, E ;
Loffe, E .
GENE THERAPY, 2005, 12 (Suppl 1) :S5-S17
[7]   IMMUNITY TO CANINE ADENOVIRUS RESPIRATORY-DISEASE - A COMPARISON OF ATTENUATED CAV-1 AND CAV-2 VACCINES [J].
CORNWELL, HJC ;
KOPTOPOULOS, G ;
THOMPSON, H ;
MCCANDLISH, IAP ;
WRIGHT, NG .
VETERINARY RECORD, 1982, 110 (02) :27-32
[8]   Purification of adenovirus and adeno-associated virus: Comparison of novel membrane-based technology to conventional techniques [J].
Duffy, AM ;
O'Doherty, AM ;
O'Brien, T ;
Strappe, PM .
GENE THERAPY, 2005, 12 (Suppl 1) :S62-S72
[9]   A new scalable method for the purification of recombinant adenovirus vectors [J].
Green, AP ;
Huang, JJ ;
Scott, MO ;
Kierstead, TD ;
Beaupré, I ;
Gao, GP ;
Wilson, JM .
HUMAN GENE THERAPY, 2002, 13 (16) :1921-1934
[10]   A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model [J].
Hemminki, A ;
Kanerva, A ;
Kremer, EJ ;
Bauerschmitz, GJ ;
Smith, BF ;
Liu, B ;
Wang, MH ;
Desmond, RA ;
Keriel, A ;
Barnett, B ;
Baker, HJ ;
Siegal, GP ;
Curiel, DT .
MOLECULAR THERAPY, 2003, 7 (02) :163-173